Biocon eyes $30b US insulin market via its biosimilars
![](https://img.etimg.com/thumb/msid-87247533,width-1070,height-580,imgsize-25864,overlay-economictimes/photo.jpg)
With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the US, helping it make a strong entry into that market. This also proves that the company has the science and vertical integration required to get to the US market, it said.
via Economictimes
Post a Comment